Pfizer and GSK shots to prevent RSV get health panel approval

Shots from Pfizer and GSK that prevent respiratory syncytial virus received backing from a panel of US public health advisers for use in older adults, paving the way for the preventives to be used in a vulnerable population. In two separate votes Wednesday, advisers to the Centers for Disease Control and Prevention recommended the shots in people aged 60 and older after consultation with their doctors. CDC Director Rochelle Walensky will decide whether to finalize the recommendations.